This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Yukihisa Sawa: Innovator in Monoclonal Antibodies
Introduction
Yukihisa Sawa is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has the potential to impact various therapeutic applications.
Latest Patents
Yukihisa Sawa holds a patent for "Anti-human XCR1 antibodies." The objective of this invention is to provide a monoclonal antibody that binds to human XCR1. This antibody is designed to bind to linear or discontinuous epitopes that comprise at least three amino acids selected from a specific group within the amino acid sequence of SEQ ID NO: 91. This innovation represents a step forward in targeted therapies.
Career Highlights
Yukihisa Sawa is currently associated with Eisai R&D Management Co., Ltd. His role in the company allows him to work on cutting-edge research and development projects. His expertise in monoclonal antibodies positions him as a key player in the biotechnology sector.
Collaborations
Yukihisa has collaborated with notable colleagues such as Yoshimasa Sakamoto and Miyuki Nishimura. These collaborations enhance the research environment and foster innovation within the team.
Conclusion
Yukihisa Sawa's contributions to the field of monoclonal antibodies exemplify the importance of innovation in biotechnology. His patent on anti-human XCR1 antibodies showcases his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile